Preserving Salivary Gland Function After Radioiodine Therapy for Thyroid Cancer

甲状腺癌放射性碘治疗后保留唾液腺功能

• 批准号: 8588546
• 负责人: Sissy M Jhiang
• 金额: $ 29.24万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-25 至 2018-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8588546
• 关键词: Adverse effects; Anatomy; Biological Markers; Cancer Center; Cancer Patient; Cancer Survivor; Case-Control Studies; Categories; Cells; Chronic; Chronic Disease; Clinical; Clinical Management; Dental caries; Development; Ductal Epithelial Cell; Early Diagnosis; Ensure; Exposure to; Functional disorder; Future; Genetic Heterogeneity; Goals; Hour; Image; Individual; Infusion procedures; Injury; Instruction; Intervention; Iodides; Lead; Life; Malignant neoplasm of thyroid; Measures; Mediating; MicroRNAs; Monitor; Morbidity - disease rate; Mus; Ohio; Pain; Patients; Periodontal Diseases; Predictive Value; Predisposition; Prevention strategy; Preventive Intervention; Prospective Studies; Protein Isoforms; Questionnaires; Radioactivity; Recording of previous events; Recruitment Activity; Recurrence; Regimen; Reporting; Resistance; Risk Factors; Saliva; Salivary; Salivary Glands; Sialadenitis; Sialography; Side; Small Interfering RNA; Staging; Staining method; Stains; Swelling; Testing; Therapeutic Intervention; Thyroid Gland; Time; Tissues; Universities; Xerostomia; case control; effective therapy; follow-up; inhibitor/antagonist; novel; novel strategies; outcome forecast; prevent; saliva proteome; single photon emission computed tomography; small hairpin RNA; standard care; symporter; uptake

Radioiodine (131 1) targets thyroid tissues and has been an effective and standard treatment for differentiated thyroid cancers for many years. However, the Na +/| symporter (NIS), which mediates active iodide uptake into thyroid follicular cells, is also abundantly expressed in salivary ductal cells. Accordingly, many I-treated thyroid cancer survivors suffer from life-long morbidity of l-induced salivary gland (SG) dysfunction, including recurrent sialadenitis, persistent xerostomia, and progressive susceptibility to dental caries and periodontal disease. In this proposal, we aim to explore novel approaches to prevent I-induced SG damage in thyroid cancer patients, and to identify protective saliva biomarkers for patients' susceptibility to progressive I-induced SG dysfunction. Two specific aims are identified: (1) Transient silencing/inhibition of salivary NIS to eliminate salivary "^1 accumulation during radioiodine therapy; and (2) Identify protective saliva biomarkers and underlying pathobiology for I-induced SG dysfunction. Upon successful completion of the proposed studies, our novel prevention strategy promises to eliminate I-induced SG damage or at least dramatically reduce its occurrence among thyroid cancer survivors who will receive I therapy. We will be able to use quantifiable saliva biomarkers or SG anatomic changes to monitor the onset and progression of SG dysfunction induced by "^1 such that personalized intervention strategies can be applied to patients in a timely manner. We will determine whether saliva biomarkers detected in the early stage of salivary dysfunction induced by I are predictive of future progression to chronic disease. We may also distinguish patients who are more susceptible or resistant to develop life-long morbidity of I-induced SG dysfunction for differential clinical management.

放射性碘（131 1）靶向甲状腺组织，已成为分化性甲状腺疾病的有效标准治疗方法